The blockade of RIPK2 activation by an intrarectal administration of a plasmid harboring RIPK2-specific siRNA encapsulated in the hemagglutinating virus of Japan envelope efficiently prevented the development of DSS- and TNBS-induced colitis in mice with intact NOD1 and NOD2, whereas colitis was manifested in animals that received intrarectal administration of the plasmid carrying control siRNA (Watanabe et al., 2019). The gene discussed is NOD2; the disease is colitis.